{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T06:07:33Z","timestamp":1792994853165,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jhep.2021.03.004","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:30:16Z","timestamp":1615509016000},"page":"1472-1482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["Treatment failure with DAA therapy: Importance of resistance"],"prefix":"10.1016","volume":"74","author":[{"given":"Christoph","family":"Sarrazin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.03.004_bib1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","author":"Spearman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2021.03.004_bib2","doi-asserted-by":"crossref","first-page":"a037093","DOI":"10.1101\/cshperspect.a037093","article-title":"Hepatitis C virus replication","volume":"10","author":"Tabata","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jhep.2021.03.004_bib3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hep.20882","article-title":"New kinetic models for the hepatitis C virus","volume":"42","author":"Perelson","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.03.004_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/vaccines5030024","article-title":"Immune evasion strategies during chronic hepatitis B and C virus infection","volume":"5","author":"Ortega-Prieto","year":"2017","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jhep.2021.03.004_bib5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.03.004_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region","volume":"116","author":"Sarrazin","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2021.03.004_bib9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","article-title":"Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses","volume":"67","author":"Welzel","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib10","first-page":"1393A","article-title":"Prevalence and impact of baseline NS5A Resistance-Associated Variants (RAVs) on the efficacy of elbasvir\/grazoprevir (EBR\/GZR) against GT1a infection","volume":"62","author":"Jacobson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.03.004_bib11","doi-asserted-by":"crossref","first-page":"104574","DOI":"10.1016\/j.antiviral.2019.104574","article-title":"Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naive subjects","volume":"170","author":"Han","year":"2019","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2021.03.004_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.gastro.2019.05.007","article-title":"Amino acid substitutions in genotype 3a hepatitis C virus polymerase protein affect responses to sofosbuvir","volume":"157","author":"Wing","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.03.004_bib13","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jhep.2019.07.025","article-title":"Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: implications for global elimination of hepatitis C","volume":"71","author":"Childs","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.03.004_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/liv.14591","article-title":"Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions","author":"Dietz","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.03.004_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3851\/IMP3120","article-title":"Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin","volume":"22","author":"McPhee","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2021.03.004_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cgh.2019.10.051","article-title":"Efficacy of retreatment after failed direct-acting antiviral therapy in patients with HCV genotype 1-3 infections","volume":"19","author":"Dietz","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2017.11.032","article-title":"Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir\/velpatasvir in the phase III studies","volume":"68","author":"Hezode","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib20","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2021.03.004_bib21","first-page":"373A","article-title":"Sofosbuvir\/velpatasvir for patients with chronic genotype 3 HCV\u00a0infection with compensated cirrhosis: an integrated analysis of\u00a0phase 2 and phase 3 clinical trials","volume":"68","author":"Roberts","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.03.004_bib22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jvh.13116","article-title":"In\u00a0vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6","volume":"26","author":"Dvory-Sobol","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2021.03.004_bib23","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/j.gastro.2018.06.042","article-title":"Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis","volume":"155","author":"Esteban","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.03.004_bib24","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2021.03.004_bib25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.gastro.2016.09.045","article-title":"Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection","volume":"152","author":"Kwo","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.03.004_bib26","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2021.03.004_bib27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 Weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2021.03.004_bib29","article-title":"Pooled resistance analysis in patients with hepatitis C virus genotype 1 to 6 infection treated with glecaprevir-pibrentasvir in phase 2 and 3 clinical trials","volume":"62","author":"Krishnan","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2021.03.004_bib30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/apt.15633","article-title":"Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir\/pibrentasvir among chronic hepatitis C patients","volume":"51","author":"Singh","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.03.004_bib31","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2021.03.004_bib32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib33","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals","volume":"154","author":"Dietz","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.03.004_bib34","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/jvh.13322","article-title":"Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection","volume":"27","author":"Dietz","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2021.03.004_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2021.03.004_bib36","first-page":"S203","article-title":"No impact of RASs on the high efficacy of SOF\/VEL\/VOX for 8 weeks in DAA-na\u00efve patients: an integrated resistance analysis of the POLARIS-2 and POLARIS-3 studies","volume":"66","author":"Wyles","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jhep.2020.11.017","article-title":"Failure to voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy","volume":"74","author":"Dietz","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib38","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1093\/jac\/dkaa304","article-title":"Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir\/pibrentasvir regimen","volume":"75","author":"de Salazar","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jhep.2021.03.004_bib39","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1-7 and escape variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.03.004_bib40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/hep.30647","article-title":"Evolutionary pathways to persistence of highly fit and resistant hepatitis C virus protease inhibitor escape variants","volume":"70","author":"Jensen","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.03.004_bib41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-0039-3402001","article-title":"NS5A-P32 deletion in hepatitis C genotype 1b infection is the most refractory treatment-mediated amino acid change exhibiting resistance to all NS5A inhibitors","volume":"40","author":"Hikita","year":"2020","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2021.03.004_bib42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12985-018-0936-4","article-title":"A\u00a03-year follow-up study after treatment with simeprevir in combination with pegylated interferon-alpha and ribavirin for chronic hepatitis C virus infection","volume":"15","author":"Zoulim","year":"2018","journal-title":"Virol J"},{"key":"10.1016\/j.jhep.2021.03.004_bib43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcv.2011.08.015","article-title":"Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir","volume":"52","author":"Susser","year":"2011","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.jhep.2021.03.004_bib44","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3851\/IMP3253","article-title":"Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection","volume":"23","author":"Lahser","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2021.03.004_bib45","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/S0618-8278(19)30197-5","article-title":"Analysis of long-term persistence of HCV resistance-associated substitutions within NS3, NS5A and NS5B in genotype 1 and 3 after DAA treatment failure","volume":"70","author":"Dietz","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3851\/IMP3181","article-title":"Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir","volume":"23","author":"Wyles","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2021.03.004_bib47","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2893.2011.01449.x","article-title":"Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b","volume":"19","author":"Vermehren","year":"2012","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2021.03.004_bib48","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1128\/AAC.04911-14","article-title":"Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3\/4A protease inhibitor telaprevir","volume":"59","author":"Susser","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2021.03.004_bib49","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2012.07.117","article-title":"Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy","volume":"143","author":"Lenz","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.03.004_bib50","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/S0168-8278(15)30012-X","article-title":"Retreatment of patients who failed 8 or 12 weeks of ledipasvir\/sofosbuvir-based regimens with ledipasvir\/sofosbuvir for 24 weeks","volume":"62","author":"Lawitz","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib51","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.3748\/wjg.v23.i46.8120","article-title":"Retreatment of patients with treatment failure of direct-acting antivirals: focus on hepatitis C virus genotype 1b","volume":"23","author":"Kanda","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.03.004_bib52","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s12328-020-01182-9","article-title":"Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection","volume":"13","author":"Takaki","year":"2020","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.03.004_bib53","first-page":"446A","article-title":"Retreatment of patients who failed direct-acting antiviral (DAA) therapies: real world experience from a large European hepatitis C resistance database","volume":"64","author":"Vermehren","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.03.004_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185728","article-title":"Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: interim evaluations from the PITER network","volume":"12","author":"Kondili","year":"2017","journal-title":"PloS one"},{"key":"10.1016\/j.jhep.2021.03.004_bib55","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2019.06.022","article-title":"High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world","volume":"71","author":"Perez","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib56","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/cid\/cix916","article-title":"Retreatment with sofosbuvir plus grazoprevir\/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed an NS5A- or NS3-containing regimen: the ANRS HC34 REVENGE study","volume":"66","author":"de Ledinghen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2021.03.004_bib57","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1053\/j.gastro.2019.08.008","article-title":"Efficacy of glecaprevir and pibrentasvir in patients with genotype 1 hepatitis C virus infection with treatment failure after NS5A inhibitor plus sofosbuvir therapy","volume":"157","author":"Lok","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.03.004_bib58","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2021.03.004_bib59","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","article-title":"No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients","volume":"69","author":"Sarrazin","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib60","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2019.07.020","article-title":"Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients with previous DAA failure","volume":"71","author":"Degasperi","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib61","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs","volume":"71","author":"Llaneras","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib62","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/jvh.13115","article-title":"Real-world effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients","volume":"26","author":"Belperio","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2021.03.004_bib63","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir\/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics","author":"Papaluca","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2021.03.004_bib64","first-page":"841","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: results from the German Hepatitis C-Registry (DHC-R)","volume":"58","author":"Vermehren","year":"2020","journal-title":"Z\u00a0Gastroenterologie"},{"key":"10.1016\/j.jhep.2021.03.004_bib65","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1016\/S0168-8278(20)31174-0","article-title":"Real-world retreatment of HCV-infected patients with prior failure to direct antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir","volume":"73","author":"Smith","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib66","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1016\/S0168-8278(20)31209-5","article-title":"Real-world effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir as a hepatitis C virus infection salvage treatment","volume":"73","author":"Janjua","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib67","doi-asserted-by":"crossref","first-page":"S846","DOI":"10.1016\/S0168-8278(20)32136-X","article-title":"Pangenotypic therapies glecaprevir-pibrentasvir (G-P) and sofosbuvir-velpatasvir-voxilaprevir (S-V-V) after failure with interferon (IFN)-frei direct acting antiviral (DAA) treatment for hepatitis C","volume":"73","author":"Flamm","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib68","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.004_bib69","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.14309\/ajg.0000000000000248","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir for previous treatment failures with glecaprevir\/pibrentasvir in chronic hepatitis C infection","volume":"114","author":"Pearlman","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.03.004_bib70","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jhep.2019.01.031","article-title":"Retreatment of patients who failed glecaprevir\/pibrentasvir treatment for hepatitis C virus infection","volume":"70","author":"Wyles","year":"2019","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821001690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821001690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:41:44Z","timestamp":1759174904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821001690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0168827821001690"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.03.004","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment failure with DAA therapy: Importance of resistance","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}